These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22626986)

  • 1. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.
    Ehninger D
    Neuropharmacology; 2013 May; 68():97-105. PubMed ID: 22626986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
    Waltereit R; Feucht M; de Vries MC; Huemer J; Roessner V; de Vries PJ
    Z Kinder Jugendpsychiatr Psychother; 2019 Mar; 47(2):139-153. PubMed ID: 30080117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of mTOR in tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberous sclerosis complex.
    DiMario FJ; Sahin M; Ebrahimi-Fakhari D
    Pediatr Clin North Am; 2015 Jun; 62(3):633-48. PubMed ID: 26022167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis.
    Ehninger D; de Vries PJ; Silva AJ
    J Intellect Disabil Res; 2009 Oct; 53(10):838-51. PubMed ID: 19694899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].
    García-Peñas JJ; Carreras-Sááez I
    Rev Neurol; 2013 Feb; 56 Suppl 1():S153-61. PubMed ID: 23446718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
    Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
    Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.
    Moavero R; Romagnoli G; Graziola F; Curatolo P
    Semin Pediatr Neurol; 2015 Dec; 22(4):282-94. PubMed ID: 26706015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
    Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.
    Way SW; Rozas NS; Wu HC; McKenna J; Reith RM; Hashmi SS; Dash PK; Gambello MJ
    Hum Mol Genet; 2012 Jul; 21(14):3226-36. PubMed ID: 22532572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated.
    Cabrera-López C; Bullich G; Martí T; Català V; Ballarín J; Bissler JJ; Harris PC; Ars E; Torra R
    BMC Med Genet; 2015 Jun; 16():39. PubMed ID: 26077033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in neurobiology of Tuberous Sclerosis Complex.
    Napolioni V; Moavero R; Curatolo P
    Brain Dev; 2009 Feb; 31(2):104-13. PubMed ID: 19028034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes.
    Kútna V; O'Leary VB; Newman E; Hoschl C; Ovsepian SV
    Neurotherapeutics; 2021 Apr; 18(2):845-858. PubMed ID: 33398801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberous sclerosis complex: disease modifiers and treatments.
    Au KS; Ward CH; Northrup H
    Curr Opin Pediatr; 2008 Dec; 20(6):628-33. PubMed ID: 19005330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.